@article{TCR14118,
author = {Qian Lin and Leina Ma and Dong Wang and Zhihong Yang and Jin Wang and Zhantao Liu and Guohui Jiang},
title = {A novel Camptothecin analogue inhibits colon cancer development and downregulates the expression of miR-155 in vivo and in vitro},
journal = {Translational Cancer Research},
volume = {6},
number = {3},
year = {2017},
keywords = {},
abstract = {Background: FL118 is a newly discovered camptothecin analogue that exerts anti-tumor activity on a wide range of cancers; however, the molecular mechanism underlying FL118’s antitumor activity is still far from being completely understood. MicroRNAs (miRNAs) are believed to play an important role in the progression of human malignancies, and increasing evidence shows that these small RNAs also mediates the tumor-suppressing activity of many natural and/or synthetic compounds. Our previous studies indicated that miR-155, which has been confirmed as an oncogenic miRNA in colorectal carcinoma was significantly downregulated after the treatment of FL118.
Methods: MTT assay, scratch wound assay, BrdU cell proliferation assay and flow cytometry were employed to detect HCT-116 cell viability, mobility, proliferation, apoptosis and cell cycle under the treatment of FL118, respectively. Xenograft models were established to observe the effect of FL118 on tumor growth in vivo. Also, qRT-PCR was performed to detect the level of miR-155 in colon cancer cells and tumor samples after FL118 administration.
Results: Our results showed that FL118 induced cell apoptosis, inhibited cell viability and mobility, suppressed cell proliferation and limited the growth of colon cancer. The levels of miR-155 were downregulated significantly (P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/14118}
}